Your session is about to expire
← Back to Search
LMB-100 + Ipilimumab for Mesothelioma
Study Summary
This trial is testing a combination of drugs to see if it is safe and effective in treating mesothelioma.
- Mesothelioma
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2021 Phase 1 & 2 trial • 40 Patients • NCT02810418Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- Your heart's electrical activity takes too long to reset.You have had lung inflammation in the past that needed steroids, or you currently have lung inflammation.You have HIV.You have a current infection of Hepatitis B or C.You have another type of cancer that has been getting worse or needed treatment in the last 2 years.You have a disease that can be treated with an injection of LMB-100 directly into the tumor.You have taken LMB-100 before.You have had a very serious allergic reaction to anti-CTLA4 therapies or any of their ingredients.You have a measurable disease according to specific guidelines, even if the disease is in an area previously treated with radiation.You have had radiation treatment in the area where the study drug will be given.You have a tumor tissue sample available, or you can get a new biopsy of a tumor that hasn't been treated with radiation before. It's best if the sample is in a tissue block, but slides or a new biopsy are also okay.Your tumor must be a specific type determined by a special lab test. If your tumor has two different types, one of them must make up more than half of the tumor.You must have received certain types of cancer treatments in the past, including immune checkpoint therapy and platinum-based chemotherapy.You should be in good physical condition with few or no symptoms from your cancer. This will be checked within 28 days before starting the study treatment.Your kidney function should be calculated according to the hospital's standard method.Your heart's pumping function should be good, with a measurement of more than 50%.You have mesothelioma that cannot be treated with surgery to potentially cure it.You currently have an infection that needs treatment with medication throughout your body.You have cancer that has spread to your brain or spinal cord.You have a significant buildup of fluid around your heart.You are currently taking medication to prevent blood clots.You have a condition that weakens your immune system, or you are taking strong medication that weakens your immune system.
- Group 1: 1/Intra-tumoral LMB-100 Administration
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are there additional instances of scientific research involving LMB-100?
"The current clinical landscape for LMB-100 is quite robust, with 318 ongoing studies and 38 in the advanced phase 3. Pittsburgh, Pennsylvania has a considerable number of trials operating however there are over 20362 sites providing care to patients worldwide."
What is the aggregate number of participants involved in this experiment?
"Affirmative. The clinical trial website indicates that this trial is actively recruiting patients and has been since June 11th 2021. As of October 4 2022, the study seeks 20 participants from a single location."
What outcomes is this experiment aiming to manifest?
"The primary objective of this 21-day experiment is to evaluate the safety of LMB-100. Secondary endpoints are defined as the fraction of participants that experience a partial or complete response, median time from initial treatment to death due to any cause (overall survival), and average length between meeting criteria for response and documentation of recurrence/progression (duration of response)."
What therapeutic indications does LMB-100 usually address?
"LMB-100 is the go-to treatment for cutaneous melanoma and can be beneficial in treating complete resection, liver carcinoma, and metastatic melanoma."
Is there an opportunity to join this experiment at the present time?
"Per the clinicaltrials.gov portal, this study is still open for enrollment and has been since June 11th 2021. The details of the trial were last revised in October 4 2022."
Has LMB-100 acquired the approval of the Food and Drug Administration?
"There is only limited evidence for the safety and efficacy of LMB-100, so it has been given a score of 1."
Share this study with friends
Copy Link
Messenger